Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The FAME trial has been given the green light and is now open to recruitment.

The FAME (Fractured Ankle Management Evaluation) Trial has now received OCTRU Green Light approval to start recruitment!

 

This trial is comparing two different types of treatment for a broken ankle – a close contact cast to hold the bones correctly while they heal versus an operation where the broken bones are held using plates and screws. The trial aims to recruit 890 patients across at least 20 NHS hospitals.

Similar stories

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Emergency departments to use the FORCE pathway for wrist fractures in children

New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.